It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Achieving exceptional scientific outcomes through connected drug discovery.
Sygnature Discovery is a contract research organisation with an excellent track record. We’re reshaping drug discovery by uniting technologies, disciplines and talent across Europe and North America.
World-leading drug discovery solutions, accelerating your compound to the clinic.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
We offer deep expertise across the full range of drug discovery solutions.
We’re not only experts in the core disciplines and stages of drug discovery but have experience across a variety of diseases, target classes and modalities. Our scientists work together and as an extension of your team, powered by AI, automation and a shared commitment to your success.
We deliver world-class scientific expertise and flexible services across every discipline in preclinical discovery.
We’re ready to partner with you, from targeted project support to fully integrated discovery programs. Our scientists work as an extension of your team, powered by AI, automation, and a shared commitment to your success.
Accelerate from target to candidate with fully integrated drug discovery programs. Our 700+ experts collaborate across every stage, from target identification to pre-clinical development. Without an internal pipeline, we’re completely focused on your success. Global expertise, co-located teams, and scientific excellence drive faster, high quality outcomes.
Design smarter compounds with AI-powered modelling and deep scientific expertise. Our integrated CADD solutions combine structure and ligand-based design, predictive modelling, and secure data access to reduce risk and timelines. Collaborative workflows and advanced informatics drive innovation from target analysis to lead optimization, enabling faster, more informed decisions
Delivering high-quality proteins and structural insights to advance drug discovery. Our global team combines expertise in expression, purification and characterization with in-house X-ray crystallography, cryo-EM, and NMR. From complex targets to fragment screening, we provide tailored solutions and collaborative partnerships that drive confident decisions and innovative design.
Tailored bioscience solutions integrate seamlessly into your research. Our expert teams design robust assays, generate reliable data, and overcome complex biological challenges. From target validation to candidate nomination, we combine advanced technologies with collaborative problem-solving to enable confident decisions and keep your drug discovery programs moving forward.
Global chemistry expertise combined with AI-enhanced design and collaborative strategies to create candidate-quality molecules. Our integrated teams span medicinal, synthetic, process, and high-throughput chemistry, scaling from milligram to kilogram. With transparent communication and tailored approaches, we help you overcome complexity and advance discovery with confidence and scientific precision.
Integrated DMPK solutions combine advanced assays, predictive modelling, and translational strategies to reduce risk and guide confident decisions. From early ADME screening to candidate nomination, our experts deliver phase-appropriate insights across pharmacokinetics, bioanalysis, and biotransformation ensuring reliable data, optimized dose strategies, and seamless collaboration throughout the drug discovery pipeline.
High-quality in vivo pharmacology data supports confident decisions across drug discovery. Our team combines deep expertise, validated models, and advanced technologies to deliver clinically relevant insights. From pharmacokinetics and biomarkers to disease-specific models and exploratory toxicology, tailored study design and multidisciplinary collaboration ensure robust results and streamlined progression.
Technology-agnostic formulation strategies built on solid-state characterization and data-driven insight overcome barriers to clinical success. Multidisciplinary expertise delivers robust, scalable solutions tailored to each molecule’s properties, supporting confident development and regulatory readiness throughout the drug discovery journey.
We offer specialist expertise across a range of modalities, target classes and therapeutic areas.
Whether we’re collaborating on integrated or stand alone projects, our range of biological and chemical expertise means we can solve even the most difficult drug discovery challenges.
Modalities
Our scientists have considerable experience in a wide range of modalities. We can advise on the best fit modality for your project and provide the most appropriate drug discovery solutions, tailored to your needs.
Our teams combine target expertise and CADD-driven analysis to identify the right strategy for your target. We’re focused on precise, efficient discovery of high-quality candidates.
We have many years of experience across a range of therapeutic areas including oncology, neuroscience, anti-infectives and metabolic, inflammatory, fibrotic & respiratory diseases.
At Sygnature Discovery we make drug discovery more connected, efficient and effective, by uniting advanced technologies, diverse disciplines and global expertise.
We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment.
Over the past 20 years, we’ve earned a track record of real impact: more than 60 advanced candidates, 200+ patents filed and 200+ active projects. Over 90% of our customers choose to stay with us, from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges.
Since 2011, we’ve advanced more than 60 candidates across a range of key therapeutic areas, from immunology and oncology to neuroscience and infectious disease, including 23 preclinical and 36 clinical assets, with 2 approved. This breadth demonstrates our ability to drive complex, high-value discovery programs into the clinic and to lay the foundations for a meaningful impact on patients.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
At Sygnature Discovery we’re looking for people that share our passion for drug discovery research. We recruit great scientists with the same ambition to improve people’s health through their work. We offer varied careers across multiple drug discovery disciplines.
